PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study (Q81236488)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17849460%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

title

PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17849460%20AND%20SRC:MED&resulttype=core&format=json

myeloproliferative disorders

7 January 2020

main subject

1 reference

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17849460%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Guillermo Garcia-Manero

5

object named as

Guillermo Garcia-Manero

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17849460%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

3

Jorge Cortes

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17849460%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

10

Francis Giles

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17849460%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

1

Elias Jabbour

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17849460%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

2

Hagop Kantarjian

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17849460%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

8

Mary Ann Richie

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17849460%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

author name string

Deborah Thomas

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17849460%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Alessandra Ferrajoli

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17849460%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Stefan Faderl

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17849460%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Miloslav Beran

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17849460%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

publication date

1 November 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17849460%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17849460%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

volume

110

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17849460%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17849460%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

page(s)

2012-2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17849460%20AND%20SRC:MED&resulttype=core&format=json

bcr/abl-negative, classic myeloproliferative disorders: diagnosis and treatment

7 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23018

7 January 2021

Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23018

7 January 2021

Long term treatment of myeloproliferative disease with interferon-alpha-2b: feasibility and efficacy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23018

7 January 2021

Treatment of essential thrombocythaemia by alpha-interferon

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23018

7 January 2021

Structural and biologic characterization of pegylated recombinant IFN-alpha2b

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23018

7 January 2021

Identification of the major positional isomer of pegylated interferon alpha-2b

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23018

7 January 2021

A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23018

7 January 2021

Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23018

7 January 2021

Development of pegylated interferons for the treatment of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23018

7 January 2021

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23018

7 January 2021

Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23018

7 January 2021

Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23018

7 January 2021

A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23018

7 January 2021

Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23018

7 January 2021

Pegylated interferon therapy for patients with Philadelphia chromosome-negative myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23018

7 January 2021

High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23018

7 January 2021

Phase II, randomized, multicenter, comparative study of peginterferon-alpha-2a (40 kD) (Pegasys) versus interferon alpha-2a (Roferon-A) in patients with treatment-naïve, chronic-phase chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23018

7 January 2021

Identifiers

DOI

10.1002/CNCR.23018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17849460%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

1 reference